Multi-Center Prospective Study Evaluation Aspen Spinous Process Fixation System for Use in Posterolateral Fusion (PLF) in Patients With Spondylolisthesis

This study has suspended participant recruitment.
Sponsor:
Information provided by (Responsible Party):
Lanx, Inc.
ClinicalTrials.gov Identifier:
NCT01560273
First received: March 15, 2012
Last updated: May 3, 2013
Last verified: May 2012

March 15, 2012
May 3, 2013
February 2012
May 2014   (final data collection date for primary outcome measure)
Absolute change in Oswestry Disability Index (ODI) [ Time Frame: baseline to 12 months post-operative ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01560273 on ClinicalTrials.gov Archive Site
  • Title: Fusion success [ Time Frame: 12 Months post-operative ] [ Designated as safety issue: No ]
  • Change in Visual Analogue Scale (VAS) (pain) [ Time Frame: Baseline, 6 weeks, 2 weeks, 3 months, 6 months, 12 months, & 24 months ] [ Designated as safety issue: No ]
  • Neurological status [ Time Frame: Baseline, 6 weeks, 3 months, 6 months, 12 months, & 24 months ] [ Designated as safety issue: No ]
    motor functions, reflexes, and sensory
  • Operative parameters (estimate blood loss, surgery time, fluoroscopy time, and length of hospital stay) [ Designated as safety issue: No ]
  • Pain medication usage [ Time Frame: Baseline, surgery, 6 weeks, 3 months, 6 months, 12 months, & 24 months ] [ Designated as safety issue: No ]
  • Change in EQ-5D-3L [ Time Frame: Baseline, 6 weeks, 3 months, 6 months, 12 months, & 24 months ] [ Designated as safety issue: No ]
  • Change in Zurich Claudication Questionnaire [ Time Frame: Baseline, 12 months & 24 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Multi-Center Prospective Study Evaluation Aspen Spinous Process Fixation System for Use in Posterolateral Fusion (PLF) in Patients With Spondylolisthesis
A Multi-Center Prospective Study Evaluation Aspen Spinous Process Fixation System for Use in Posterolateral Fusion (PLF) in Patients With Spondylolisthesis

The purpose of this clinical investigation is to evaluate the clinical outcomes of subject with spondylolisthesis undergoing posterolateral fusion (PLF) surgery utilizing the Aspen™ Spinous Process Fixation System. The Aspen™ device will be evaluated using Oswestry Disability Index (ODI) improvement and success of fusion.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Patients 50 years and older with spondylolisthesis requiring a single level posterolateral decompression and posterolateral fusion

Spondylolisthesis
Device: Aspen Spinous Process Fixation Device
The Aspen device will be placed as posterior fixation to Posterolateral Fusion (PLF)
Aspen Spinous Process Fixation Device
The Aspen device provides supplemental posterior fixation for fusion
Intervention: Device: Aspen Spinous Process Fixation Device
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Suspended
63
May 2015
May 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age between 50 and older
  • Diagnosis of mild segmental instability on standing radiography lateral film defined as degenerative spondylolisthesis ≤ 4mm in dynamic imaging (i.e., flexion/extension)
  • Scheduled for an elective single-level posterior decompression and posterolateral fusion using AspenTM spinous process fixation system
  • Oswestry Disability Index (ODI) v 2.1 score >30%
  • Failed at least 3 months of conservative care (non-surgical) OR has clinical signs of neurological deterioration
  • Signed Informed Consent Form

Exclusion Criteria:

Pre-operative

  • Marked degenerative spondylolisthesis (>4mm)
  • Lesions requiring surgery involving two levels
  • Prior surgery at index level or adjacent level
  • Prior spinal fusion surgery
  • Isthmic or lytic spondylolisthesis
  • Incompetent or missing posterior arch at the affected level (e.g. complete laminectomy, pars defect)
  • Requires complete laminectomy at level of surgery
  • Facet joints at implant level are absent or fractured
  • Vertebral body compromise or acute fracture at implant level
  • Body mass Index (BMI) ≥ 35
  • Known allergy to titanium
  • Osteoporosis: SCORE (Simple Calculated Osteoporosis Risk Estimation) will be used to screen subjects requiring DEXA. Subjects with T-score < -2.5 will be excluded
  • Paget's disease, osteomalacia, or any other metabolic bone disease
  • Use of medications or any drug known to potentially interfere with bone/soft tissue healing (e.g. chronic systemic steroids)
  • Planned use of additional segmental fixation (eg. facet screws, anterior/lateral plating, anchored cages)
  • Use of Bone Morphogenetic Protein (BMP)*
  • Unlikely to comply with the follow-up evaluation schedule
  • In the opinion of the Investigator, Subject has history of chemical substance dependency or significant psychosocial disturbance that may impact the outcome or study participation
  • Active participation in a clinical trial of another drug or device
  • Active systemic infection or any other health condition that would preclude surgery
  • History of invasive malignancy, except if the subject has received treatment and displayed no clinical signs and symptoms for at least five years
  • Pregnant or planning to become pregnant during study participation
  • Involvement in active litigation related to back problems at the time of screening
  • Direct involvement in the execution of this protocol
  • Pre-existing conditions that could interfere with the evaluation of outcome measures (e.g. musculoskeletal, neuromuscular, etc.)

Intra-operative Exclusion

  • Intra-operative visualization of a > 4mm spondylolisthesis not previously noted radiographically
  • Any change in the surgical procedure that violates the inclusion/exclusion criteria. (eg. switching to double level procedure; placing pedicle screws as posterior fixation).
Both
50 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01560273
ASP-11-002
No
Lanx, Inc.
Lanx, Inc.
Not Provided
Principal Investigator: Shah Goodman Campbell brain and Spine
Lanx, Inc.
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP